Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (32)

2024

  1. Lipoprotein(a) and Long-Term Recurrent Infarction After an Acute Myocardial Infarction

    American Journal of Cardiology, Vol. 211, pp. 9-16

  2. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 34, Núm. 1, pp. 90-97

2023

  1. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

    The American journal of cardiology, Vol. 205, pp. 321-324

  2. Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 2, pp. 157-164

  3. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

    Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75

  4. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

    Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611

2022

  1. Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

    Journal of Clinical Medicine, Vol. 11, Núm. 11

  2. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  3. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  4. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2021

  1. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events

    Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169

  2. Direct oral anticoagulants versus warfarin in octogenarians with nonvalvular atrial fibrillation: A systematic review and meta‐analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 22

  3. Mortality associated with cardiovascular disease in patients with COVID-19

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38

  4. Soluble ST2 and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

    Journal of Cardiac Failure, Vol. 27, Núm. 4, pp. 427-434

2020

  1. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

    American Journal of Medicine, Vol. 133, Núm. 3, pp. 370-380.e4

  2. Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 3320-3328

  3. Estimation of the major cardiovascular events prevention with Inclisiran

    Atherosclerosis, Vol. 313, pp. 76-80

  4. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials

    Journal of Diabetes and Metabolic Disorders, Vol. 19, Núm. 2, pp. 759-765

  5. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects

    Journal of the American Medical Directors Association, Vol. 21, Núm. 7, pp. 915-918

2019

  1. Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors

    Revista Espanola de Cardiologia